The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | CheckMate 649: nivolumab and chemotherapy or ipilimumab in GC/GEJC/EAC
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides some background on the Phase III CheckMate 649 trial (NCT02872116) of nivolumab and chemotherapy or ipilimumab in the first line setting for patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC). Whilst nivolumab with chemotherapy demonstrated survival benefit, addition of ipilimumab did not confer an overall survival advantage. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
